Unresectable Breast Cancer
Oncology
0
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
ADC
2100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
DS
Daiichi SankyoChina - Shanghai
2 programsTrastuzumab deruxtecanN/AADC1 trial
Trastuzumab deruxtecanN/AADC1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
2028
Daiichi SankyoTrastuzumab deruxtecan
Daiichi SankyoTrastuzumab deruxtecan
Clinical Trials (2)
Total enrollment: 1,177 patients across 2 trials
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
Start: Apr 2024Est. completion: Jul 202522 patients
N/ACompleted
DESTINY Breast Respond HER2-low Europe
Start: Oct 2023Est. completion: Sep 20281,155 patients
N/ARecruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
4h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
4h ago
Office Administrator
SystImmune
4h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
4h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
4h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
4h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 1,177 patients
1 companies competing in this space